 |
市场调查报告书
商品编码
1454239
全球急性肌张力不全症市场：按药物类别、年龄层、分销管道和地区划分。Global Acute Dystonia Market, By Drug Class, By Age Group, By Distribution Channel, By Geography . |
||||||
价格
简介目录
2023年，全球急性肌张力不全症市场价值为1.207亿美元，预计到2031年将达到1.55亿美元，2024年至2031年的年复合成长率（CAGR）预计为3.2%。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年 | 2023年 | 2023/2024年市场规模 | 1.207 亿美元 |
| 实际资料 | 2019-2023 | 预测期 | 2024-2031 |
| 预测期2023/2024~2030/2031年复合成长率： | 3.20% | 2030/2031 年预测值 | 1.55亿美元 |
图 1. 2024 年急性肌张力不全症的全球市场占有率（%），依地区划分
急性肌张力不全症是一种运动障碍，其特征是不自主的肌肉收缩，导致重复运动和异常姿势。这些收缩可能会很痛苦，通常是由突然的肌肉痉挛引起的。急性肌肌张力不全症可影响身体的任何部位，包括颈部（颈部肌肌张力不全症）、眼睛（眼肌肌张力不全症）、下巴或舌头以及四肢。这种症状有多种原因，包括：
- 药物引起的肌张力不全症：最常见的原因之一。它可能是某些药物的副作用，尤其是影响大脑多巴胺途径的抗精神病药物。
- 特发性肌张力不全症：原因不明。
- 次发性肌张力不全症：由威尔森氏症、亨丁顿舞蹈症、巴金森氏症、脑损伤或中风等潜在疾病所引起。
市场动态：
全球急性肌肌张力不全症市场是由引起急性肌肌张力不全症的神经系统疾病（如帕金森氏症、脑性麻痹和迟发性）的盛行率上升所推动的。例如，2023年8月9日，世界卫生组织（WHO）发布的一份报告发现，巴金森氏症（PD）是一种导致运动、心理健康、睡眠、疼痛和其他健康问题的脑部疾病。 2021 年，美国有近 100 万人患有帕金森氏症 (PD)，预计到 2030 年将增加至 120 万人。帕金森氏症是继阿兹海默症之后第二常见的神经退化性疾病。
此外，2022年3月，美国国家生物技术资讯中心发布的一份报告发现，美国每年每1,000名儿童中就有2.3至3.6人患有脑性麻痹。痉挛性脑性麻痹最为常见，占脑性麻痹的61%～76.9%。
本研究的主要特点
- 本报告对全球急性肌张力不全症市场进行了详细分析，并提供了以2023年为基准年的预测期（2024-2031年）的市场规模和年复合成长率（CAGR%）。
- 它还说明了各个细分市场的潜在收益成长机会，并为该市场提供了一系列有吸引力的投资提案。
- 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的主要考察。
- 它根据公司亮点、产品系列、主要亮点、绩效和策略等参数，介绍了全球急性肌肌张力不全症市场的主要企业。
- 该报告的见解使负责人和公司经营团队能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。
- 急性肌张力不全症全球市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进入者和财务分析师。
- 透过用于分析全球急性肌张力不全症市场的各种策略矩阵，将促进相关人员的决策。
目录
第一章 研究目的与前提
- 研究目标
- 先决条件
- 简称
第二章 市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
- Coherent Opportunity Map（COM）
第三章市场动态、法规及趋势分析
- 市场动态
- 肌张力不全症增加
- 与药物相关的副作用
- 了解不断变化的治疗模式
- 主要亮点
- 监管指引
- 市场趋势
- PEST分析
- 投资金筹措
- 合併、收购和合作
- 产品映射
- 识别顶级市场参与者
- 市场相关人员采取各种企业发展策略
- 按国家/地区分類的医疗保健支出
第四章全球急性肌张力不全症市场－冠状病毒（COVID-19）大流行的影响
- 新型冠状病毒感染疾病（COVID-19）的流行病学
- 供需面分析
- 经济影响
第五章全球急性肌张力不全症市场，依药物类别，2019-2031
- 抗胆碱能药物
- 苯二氮平类
- 其他（神经毒素等）
第六章 全球急性肌张力不全症市场，依年龄层划分，2019-2031
- 孩子
- 成人
第七章全球急性肌张力不全症市场，按分销管道，2019-2031
- 医院药房
- 零售药房
- 网路药房
第八章全球急性肌张力不全症市场，按地区，2019-2031
- 北美洲
- 美国
- 加拿大
- 欧洲
- 德国
- 英国
- 西班牙
- 法国
- 义大利
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
- ASEAN
- 其他亚太地区
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 中东
- 海湾合作委员会国家
- 以色列
- 其他中东地区
- 非洲
- 北非
- 中部非洲
- 南非
第9章 竞争格局
- 公司简介
- Fresenius Kabi
- Amar Healthcare
- Johnson &Johnson
- PAI Pharma
- Pfizer Inc.
- Souvin Pharmaceuticals Pvt.Ltd
- Bayer Healthcare
- S.Pharmachem
- Remedy Labs
- Wan Bury
- Hoffmann-La Roche Ltd
- Bausch Health Companies, Inc.
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd
- Torrent Pharmaceuticals Ltd.
- Mallinckrodt Pharmaceuticals
- Amneal Pharmaceuticals LLC
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma Ltd.
第10章
- 参考
- 调查方法
- 关于出版商
简介目录
Product Code: CMI6661
The global acute dystonia market was valued US$ 120.7 Mn in 2023 and is expected to reach US$ 155.0 Mn by 2031 growing at a compound annual growth rate (CAGR) of 3.2% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2023/2024: | US$ 120.7 Mn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 - 2031 |
| Forecast Period 2023/2024 to 2030/2031 CAGR: | 3.20% | 2030/2031 Value Projection: | US$ 155.0 Mn |
Figure 1. Global Acute Dystonia Market Share (%), By Region, 2024
Acute dystonia is a movement disorder characterized by involuntary muscle contractions that lead to repetitive movements or abnormal postures. These contractions can be painful and are often caused by a sudden onset of muscle spasms. Acute dystonia can affect any part of the body, including the neck (cervical dystonia), eyes (oculogyric crisis), jaw or tongue, and the limbs. The condition can have varying causes, including:
- Drug-induced Dystonia: One of the most common causes. It can occur as a side effect of certain medications, particularly antipsychotic drugs that affect dopamine pathways in the brain.
- Idiopathic Dystonia: Where the cause is unknown
- Secondary Dystonia: Resulting from an underlying medical condition such as Wilson's disease, Huntington's disease, Parkinson's disease, brain injury, or stroke
Market Dynamics:
The global acute dystonia market is driven by the rising prevalence of neurological disorders that can induce acute dystonia like Parkinson's disease, cerebral palsy, and tardive dyskinesia. For instance, on August 9, 2023, according to a report published by the World Health Organization (WHO), Parkinson's disease (PD) is a brain condition that causes problems with movement, mental health, sleep, pain, and other health issues. Nearly one million people in the U.S. were living with Parkinson's disease (PD) in 2021, while this number is expected to rise to 1.2 million by 2030. Parkinson's disease is the second-most common neurodegenerative disease after Alzheimer's disease.
Furthermore, in March 2022, according to a report published by the National Center for Biotechnology Information, cerebral palsy occurs in 2.3 to 3.6 out of every 1,000 children in the U.S., every year. While spastic cerebral palsy is the most common, making up 61 percent to 76.9 percent of all cerebral palsy cases.
Key Features of the Study:
- This report provides an in-depth analysis of the global acute dystonia market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global acute dystonia market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Fresenius Kabi, Amar Healthcare, Johnson & Johnson ,PAI Pharma, Pfizer Inc., Souvin Pharmaceuticals Pvt.Ltd, Bayer Healthcare, S.S.Pharmachem, Remedy Labs, Wan Bury, F. Hoffmann-La Roche Ltd, Bausch Health Companies, Inc., Viatris Inc. , Teva Pharmaceutical Industries Ltd, Torrent Pharmaceuticals Ltd., Mallinckrodt Pharmaceuticals, Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., and Aurobindo Pharma Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global acute dystonia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute dystonia market
Detailed Segmentation:
- Global Acute Dystonia Market, By Drug Class
- Anticholinergic Agents
- Benzodiazepines
- Others (Neurotoxin, etc.)
- Global Acute Dystonia Market, By Age Group
- Children
- Adult
- Global Acute Dystonia Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Acute Dystonia Market, By Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Top Companies in the Global Acute Dystonia Market:
- Fresenius Kabi
- Amar Healthcare
- Johnson & Johnson
- PAI Pharma
- Pfizer Inc.
- Souvin Pharmaceuticals Pvt.Ltd
- Bayer Healthcare
- S.Pharmachem
- Remedy Labs
- Wan Bury
- F.Hoffmann-La Roche Ltd
- Bausch Health Companies, Inc.
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd
- Torrent Pharmaceuticals Ltd.
- Mallinckrodt Pharmaceuticals
- Amneal Pharmaceuticals LLC
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Age Group
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing prevalence of dystonia
- Side effects associated with drugs
- Understanding changing treatment patterns
- Key Highlights
- Regulatory Guidelines
- Market Trends
- PEST Analysis
- Investments and Funding
- Mergers, Acquisitions, and Collaborations
- Product Mapping
- Identification of Top Market Players
- Adoption of Various Business Development Strategies by the Market players
- Healthcare Spending by Country
4. Global Acute Dystonia Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Acute Dystonia Market, By Drug Class, 2019-2031, (US$ Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Anticholinergic Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
- Benzodiazepines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
- Others (Neurotoxin, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
6. Global Acute Dystonia Market, By Age Group, 2019-2031, (US$ Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Children
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
7. Global Acute Dystonia Market, By Distribution Channel, 2019-2031, (US$ Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
8. Global Acute Dystonia Market, By Region, 2019-2031, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2020 - 2031
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019-2031,(US$ Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profile
- Fresenius Kabi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Amar Healthcare
- Johnson & Johnson
- PAI Pharma
- Pfizer Inc.
- Souvin Pharmaceuticals Pvt.Ltd
- Bayer Healthcare
- S.Pharmachem
- Remedy Labs
- Wan Bury
- Hoffmann-La Roche Ltd
- Bausch Health Companies, Inc.
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd
- Torrent Pharmaceuticals Ltd.
- Mallinckrodt Pharmaceuticals
- Amneal Pharmaceuticals LLC
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma Ltd.
- Analyst Views
10. Section
- References
- Research Methodology
- About us
